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Abstract
Solid organ transplant (SOT) recipients have a signiﬁcant risk of invasive fungal diseases (IFD) caused mainly by Candida spp. and Aspergillus
spp. Candida spp. is the most frequent agent of IFD in the transplant recipient. The absence of clinical trials and the epidemiological
differences in IFD in different transplant programmes mean that there are no deﬁnitive recommendations for the diagnosis, treatment and
prevention of IFD in SOT, so most of the evidence must be based on clinical experience.
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Hot Topics
 Solid organ transplant (SOT) recipients have a signiﬁcant risk
of invasive fungal diseases (IFD) caused mainly by Candida
spp. and Aspergillus spp.
 Candida spp. is the most frequent agent of IFD in the
transplant recipient
 The absence of clinical trials and the epidemiological
differences in IFD in different transplant programmes mean
that there are no deﬁnitive recommendations for the
diagnosis and prevention of IFD in SOT
 Universal prophylaxis against IFD should not be routinely
used in renal, liver and heart transplantation. Guided
prophylaxis in high-risk recipients will depend on the risk
factors associated with each type of transplant
 Standard treatment of Candida infections in transplant
recipients is no different from that administered
to non-neutropenic patients, although some aspects
related to drug–drug interactions and potential
toxicities associated with the use of azoles should be
considered
 Invasive aspergillosis (IA) in SOT is more a syndrome than an
infection. Treatment should be individualized according to
type of transplant, SOT recipient, type of IA and immuno-
suppression used
 Drug–drug interactions involving antifungal drugs should be
evaluated very carefully in SOT
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Introduction
Transplant patients have a signiﬁcant risk of invasive fungal
disease (IFD). IFDs caused by opportunistic fungi are univer-
sally distributed and are caused mainly by Candida spp.,
Aspergillus spp., and to a lesser extent, by Cryptococcus spp.,
fungi belonging to the Mucorales order, and other ﬁlamentous
fungi [1]. IFDs caused by endemic fungi are usually reac-
tivations but may occasionally occur as primary infections in
transplant patients who live in or visit highly endemic areas.
Candida spp. is the most frequent agent of IFD in the
transplant recipient, accounting for half of all cases in this
population. The incidence of invasive candidiasis has been
estimated at around 2% in American series of solid organ
transplantation (SOT), also including paediatric patients [1]. The
rate varies according to the organ transplanted: it is particularly
high in abdominal SOT such as intestinal, pancreas and liver
transplantation [1] and extremely uncommon after heart
transplantation [2]. A Spanish study of bloodstream infections
among transplant recipients found the incidence of global
candidaemia to be 4% [3]. The main risk factors for invasive
candidiasis are displayed in Table 1. Most cases of candidiasis
occur during the ﬁrst months after surgery. The main portal of
entry is the gastrointestinal tract, followed by endovascular
catheters and the urinary tract. Graft-transmitted candidiasis,
which ends most often in fungal arteritis, has also been
described in kidney transplantation and related to organ
contamination during recovery in the donor [4]. Candida
infections can manifest as peritonitis, empyema, candidaemia,
urinary tract infection, surgical anastomosis infection or
oesophagitis. Candidaemia is the most common clinical pre-
sentation among the invasive forms [1,5]. The overall mortality
of invasive candidiasis at 12 months is reported to be 34% [1,6].
The incidence of invasive aspergillosis (IA) ranges from 0.1
to 2.4% [1,7,8] in American series of adult and paediatric SOT
recipients. European studies have shown an incidence between
0.2 and 3.5%, depending on the type of transplant [9–11]. IA
incidence is highest among lung transplant recipients. Histor-
ically, IA was considered as a complication of the immediate
post-transplant period, but the RESITRA study has shown that
its incidence remains high after this period [9]. Risk factors for
the condition (Table 2) depend on the type of transplant [12–
16]. The most common clinical form of IA is invasive
pulmonary disease, in which case presentation is usually acute
and invasive. Aspergillosis can also cause invasive tracheo-
bronchitis in single, ulcerative or nodular forms in lung
transplant patients and may affect the bronchial anastomosis,
with dehiscence of the suture in the most severe cases.
Mortality due to IA in lung transplantation depends on the
clinical presentation; mortality for patients with tracheobron-
chitis is around 25%, but for patients who develop invasive
pulmonary disease it rises to 67–82% [17].
The incidence of cryptococcosis ranges between 0 and 1.5%
in American and European series of SOT [1,18,19], and it is the
third most common infection after candidiasis and IA [1]. The
antifungal activity of calcineurin inhibitors may explain this low
incidence [20]. Cryptococcus neoformans var. grubii has no
particular geographical predilection and causes the most
infections. C. neoformans var. neoformans is prevalent in
TABLE 1. Risk factors for invasive candidiasis
Transplant type Target population
Liver High-risk liver transplant recipients:
Major:
MELD score >30
Re-transplantation, fulminant hepatic failure,
Renal failure requiring replacement therapy,
Minor:
MELD score 20–30, split, living-donor
>40 transfusion blood products, choledochojejunostomy
(Roux-en-Y)
Renal failure not requiring replacement therapy
(CrCl <50 mL/min)
Early re-intervention, multifocal colonization/infection by
Candida spp.
Pancreas Post-perfusion pancreatitis, acute rejection and poor initial
allograft function
Vascular thrombosis, enteric drainage, anastomotic
problems, haemodialysis
Laparotomy after transplantation
Intestinal Acute rejection and poor initial allograft function,
haemodialysis, laparotomy after transplantation,
anastomotic problems, over-immunosuppression
Heart Acute rejection, haemodialysis, re-exploration after
transplantation
Cr CL, creatinine clearance; MELD, model for end-stage liver disease; over-immu-
nosuppression (high immunosuppression drug levels, under corticoid bolus).
TABLE 2. Risk factors for invasive aspergillosis
Early IA
Late IA
(>3 months
post-transplant)
Liver
transplant
Re-transplantation
Kidney failure,
especially post-transplant
Haemodialysis
Fulminant hepatic failure
Complicated surgery or
reoperation
More than 6 g of accumulative
prednisone in the third month
after transplantation
Post-transplant renal failure
Post-transplant haemodialysis
Leukopenia (<500/mm3)
Chronic graft dysfunction
Lung
transplant
Bronchial anastomotic
ischaemia or bronchial
stent placement
Acute rejection
Single-lung transplant
Aspergillus spp. colonization
before or during ﬁrst year
post-transplant
Chronic graft dysfunction
Heart
transplant
Aspergillus spp. colonization of
the respiratory tract
Re-operation
Post-transplant haemodialysis
Hypogammaglobulinaemia
(IgG < 400 mg/dl)
ICU readmission
Kidney transplantation
>2 acute rejection episodes
Kidney
transplant
Graft lost and haemodialysis
Post-transplant haemodialysis
Prolonged high corticosteroid
doses
CMV infection
Over-immunosuppression
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north-western Europe. Another Cryptococcus species, C. gattii,
has emerged in the Paciﬁc Northwest [21] and in Europe [22].
The incidence of cryptococcosis is higher in kidney and heart
transplantation. Patients who receive high doses of corticos-
teroids or monoclonal antibodies such as alemtuzumab and
inﬂiximab seem to have the highest risk of developing
disseminated cryptococcosis [23]. The mortality of crypto-
coccosis ranges from 14 to 27% [1,20]. Cryptococcosis is
typically a late-occurring infection; the time to onset usually
ranges from 16 to 21 months post-transplantation. More than
half of SOT recipients have disseminated disease or CNS
involvement and as many as 33% have fungaemia [24].
The incidence of infections by other ﬁlamentous fungi in
transplant recipients has increased in recent years [25]. Most
are caused by Mucorales (mucormycosis or zygomycosis),
although infections by Fusarium spp. and Scedosporium spp. are
also recorded. Recent American and European series of fungal
infections in SOT reported a frequency of mucormycosis lower
than 3% among all patients with fungal infection [1,26,27]. Renal
insufﬁciency, diabetes and previous administration of vorico-
nazole or caspofungin have been described as independent risk
factors for mucormycosis [28]. The most common site of
mucormycosis in SOT patients is the lungs, with a mortality of
45–50% [28,29]. Mortality can reach 73% in cerebral forms [30].
Infections by Scedosporium apiospermum account for 25% of
invasive infections caused by ﬁlamentous fungi other than
Aspergillus in some series, especially in single lung transplantation
recipients and cystic ﬁbrosis transplant patients [31].
Diagnosis
To date, blood culture (BC) has been the reference procedure
for the diagnosis of invasive candidiasis. However, its sensitivity
for detecting Candida is only 50–75% and the guidelines for
diagnosis and management of Candida infections by the
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) recommend alternative techniques [32].
If candidaemia is not present, the diagnosis of invasive
candidiasis is even more difﬁcult and requires staining
techniques and sample cultures [33,34].
Alternative procedures based on the detection and quan-
tiﬁcation of fungal biomarkers and metabolites have been
developed to improve and anticipate the detection of candi-
daemia and other forms of invasive candidiasis. However, most
of these techniques have been tested in immunocompetent
patients and their performance decreases in transplant recip-
ients and other immunosuppressed patients [35].
Two serological diagnostic methods (the combined detec-
tion of mannan and anti-mannan antibodies and the quantiﬁ-
cation of the 1,3,b-D glucan (BDG)) are recommended in the
ESCMID guidelines for candidaemia detection in adults.
Mannan and anti-mannan detection is considered speciﬁc for
identiﬁcation of Candida spp. in serum samples, and BDG
quantiﬁcation is a panfungal diagnostic method. Both tech-
niques seem to be useful for ruling out infection when serial
determinations (twice-weekly) are performed [32].
BDG detection has shown good sensitivity and speciﬁcity in
the general population for IFD diagnosis [36], higher even than
blood cultures and superior to that of mannan quantiﬁcation
[36–38]. The BDG test was also included in the EORTC/MSG
(EuropeanOrganisation for Research and Treatment of Cancer/
Mycosis Study Group) diagnostic criteria for invasive fungal
infections in 2008, for all types of patients [39]. The sensitivity
for glucan detection was >65% in most studies with a cut-off
value of 80 pg/mL, with speciﬁcity rates >80% and negative
predictive values >85%. The test is still to be validated in
children. In transplant recipients, serial detection of BDG in
serum has revealed a sensitivity for invasive candidiasis of 56%
and a speciﬁcity of 73% [34]. Using a positive cut-off of 60pg/mL,
the sensitivity of BDG in a study of lung transplantation patients
who suffered from IFD was 64%, but the speciﬁcity was 9% [40].
The limitations of this approach are due to its lack of speciﬁcity
for candidiasis detection [41]: false-positive results have been
described in patients with Pseudomonas aeruginosa bacteraemia
and in patients receiving treatment with fungus-derived antibi-
otics, intravenous immunoglobulins or albumin and with expo-
sure to gauze or other materials that contain glucans [37,42,43].
Finally, several promising PCR-based methods have been
developed for the detection of Candida spp. in clinical samples.
A published meta-analysis including 963 cases of invasive
candidiasis reported 95% sensitivity for PCR-based techniques
[44]. In a prospective study in which 20% of patients were
transplant recipients, the sensitivity and speciﬁcity of PCR for
the diagnosis of invasive candidiasis were 80% and 70%,
respectively [34].
The current guidelines issued by ESCMID and EORTC/MSG
do not recommend PCR-based methods because no stan-
dardization processes or third party validations have been
carried out to evaluate their accuracy. However, several
studies have shown a high performance of these methods for
detection of Candida infections, mainly in the ICU population.
DNA ampliﬁcation seems to be more useful than other
techniques for early detection of candidiasis and species
identiﬁcation [45]. Recent studies show DNA-based methods
to have a sensitivity >90% in ICU patients with invasive
candidiasis after abdominal surgery, even in cases with negative
BC [46]. No speciﬁc data are available for the SOT population.
Identiﬁcation of Candida species is also important, because
antifungal susceptibility is needed to achieve better outcomes.
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Several tests have been developed for the characterization of
yeast isolates. Chromogenic isolation media demonstrate
better detection rates of yeasts than traditional media; this
test may also be more cost-effective than the germ tube test
[47]. However, all these rapid methods for Candida species
identiﬁcation require subcultures rather than direct assess-
ment in positive BCs [48]. The Yeast Trafﬁc Light PNA FISH
kit test is fast and has good sensitivity for the rapid
identiﬁcation of the ﬁve Candida species found most frequently
in positive blood cultures (C. albicans, C. parapsilosis, C. tropi-
calis, C. glabrata and C. krusei) [49]. The matrix-assisted laser
desorption ionisation–time of ﬂight mass spectrometry assay
(MALDI-TOF) can also be used for the identiﬁcation of
Candida spp. in clinical microbiology laboratories [50].
The diagnosis of IA is problematic because of the risk of
colonization and contamination and the low predictive value of
respiratory sample cultures (mainly sputum). However, in a
Spanish study [51] the isolation of A. fumigatus from respiratory
tract specimens in heart transplant recipients in cases of high
suspicion was highly predictive of invasive aspergillosis. The
EORTC/MSG published consensus guidelines for the diagnosis
of IFD [39]. Three diagnostic criteria were established to deﬁne
proven, probable or possible infection: (i) patient characteris-
tics, including the immunosuppressive-host condition (such as
the use of T-cell immunosuppressants, speciﬁc monoclonal
antibodies, prolonged use of corticosteroids or a recent history
of neutropenia); (ii) clinical-radiological presentation; and (iii)
microbiological or histological reports.
Although radiological criteria include the appearance of
dense, well-circumscribed lesions, cavitations or endobronchial
lesions, other radiological lesions not included in the EORTC/
MSG consensus, such as the presence of a new or progressive
inﬁltrate or consolidation, can also be taken into consideration
for lung transplant patients [52]. The most common radiolog-
ical ﬁndings of pulmonary aspergillosis in SOT recipients are
multiple nodules or masses, which commonly appear in the
early post-transplant period [53]. Other radiographic ﬁndings
include focal areas of consolidation and nodular lesions with
cavitation. The halo sign, typically suggestive of pulmonary
aspergillosis in neutropenic patients, shows a low sensitivity in
SOT recipients, because it is often absent [54].
Together with computed tomography, the detection of
galactomannan (GM) is one of the non-culture-based tests that
most contributes to the diagnosis of IA [55]. One Spanish
study found a sensitivity of 56% in the diagnosis of IA in liver
recipients [56], but another showed a low diagnostic effec-
tiveness in the heart transplant population [11]. A meta-analy-
sis found the sensitivity of GM in SOT recipients to be 30%
[57]. The speciﬁcity of GM is reduced by the potential
false-positives, which are usually associated with the use of
b-lactams [58]. A high frequency of false-positives for GM
during the ﬁrst week after liver transplantation was observed,
a ﬁnding that was associated with b-lactam prophylaxis [59,60].
Therefore, GM should not be used for routine diagnosis or
treatment monitoring.
One potential advance in the diagnosis of IA is the use of
GM detection in bronchoalveolar lavage (BAL). A study
performed at Pittsburgh assessed the role of GM quantiﬁcation
in BAL of 116 lung recipients [61]. Based on a cut-off of 0.5, the
authors found a sensitivity of 60% and a speciﬁcity of 95%;
when the cut-off was raised to 1.0, the sensitivity was the same
and the speciﬁcity was 98% [61]. Another study with lung
recipients in Florida reported sensitivity and speciﬁcity of GM
in BAL of 100% and almost 91%, respectively, using an index
>1.0 as cut-off [62].
PCR-based methods to detect Aspergillus DNA have not
been externally validated for blood, tissue or BAL ﬂuid. The
differences in the primers, extraction/ampliﬁcation protocols
and reagents used make the validation of results between
laboratories difﬁcult. The results of a multicentre project
(EAPCRI, European Aspergillus PCR Initiative) that standard-
izes these procedures and recommendations will be available
soon [63]. As for the transplant population, a study of liver
transplant patients reported favourable results after applying
PCR-based techniques to detect Aspergillusmitochondrial DNA
in patients with positive GM titres in serum. PCR was positive
in 8/13 patients with probable or possible IA and in none of 12
patients without IA but with a false-positive GM [64].
The sensitivity and speciﬁcity of pan-Aspergillus PCR in BAL
for diagnosing IA were 100% and 88%, respectively, in a study
performed in lung transplant recipients; additionally, the
Aspergillus PCR identiﬁed one patient with IFD not diagnosed
by GM [65]. Although the EORTC/MSG consensus document
does not include PCR as a microbiological criterion, the
International Society for Heart and Lung Transplantation does
include this technique together with compatible symptoms and
radiological imaging for the diagnosis of probable IFD in lung/
heart transplant patients [61]. We consider that PCR tech-
niques warrant further studies with a view to their validation in
SOT but should not be used for routine daily diagnosis or
treatment monitoring until standardization is performed.
The sensitivity and speciﬁcity of the detection of crypto-
coccal antigen in serum and cerebrospinal ﬂuid (CSF) in
cryptococcal meningitis are very high, around 80% and 90%,
respectively [66]. Therefore, false-negatives for serum antigen
detection can be observed in SOT recipients even in the
context of disseminated disease [67]. Serum cryptococcal
antigen titres are higher in extrapulmonary, disseminated and
neurological disease [68,69]. Together with blood cultures,
these techniques are the main diagnostic tools in patients
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with suspected cryptococcosis, including the transplant
population [69,70]. Diagnosis can also be established by India
ink staining of yeasts (usually in CSF) or by culture of sterile
samples.
Pulmonary disease caused by Cryptococcus often appears as
nodular opacities on CT scans and less often as effusions or
consolidations [69]. Apart from meningeal disease, cryptococ-
comas or intraparenchymal mass lesions with hydrocephalus
may be observed in cranial MRI or CT scans of transplant
patients with neurological involvement [70].
The radiological appearance of Aspergillus or other mould
infections of the central nervous system (CNS) is variable.
Several patterns have been described, depending upon the
patients’ immune status [71].
Recommendations for the diagnosis of IFD in SOT
 Positive blood cultures that yield yeasts or, in some cases,
ﬁlamentous fungi (Scedosporium spp. and Fusarium spp.) are
considered diagnostic of IFD (AIII).
 A proven diagnosis of IFD can also be based on the
observation of tissues with invasive fungal structures or
through isolation from sterile tissue or ﬂuid samples (not
obtained through drains) (AIII).
 BDG quantiﬁcation is recommended to rule out Candida
infection in adult patients with risk factors and/or symptoms
(CIII)
 Detection of GM antigen in plasma or serum should not be
used for the routine diagnosis or treatment monitoring of IA
in SOT recipients (DIII).
 Detection of GM antigen in BAL (AII) or CSF (BIII) is useful for
the diagnosis of IA (AII) and should be performed whenever
possible.
 Special considerations for lung transplantation:
○ In the case of a positive sputum culture for Aspergillus
spp., a bronchoscopy and high-resolution chest CT scan
should be performed to rule out tracheobronchial and/
or invasive disease (BIII).
○ In the case of a positive GM in BAL, a high-resolution
chest CT scan should be performed to rule out invasive
disease (AIII).
 If invasive pulmonary aspergillosis is suspected, a high-res-
olution chest CT is recommended, because its sensitivity is
higher than the chest radiograph (AII).
 Therapeutic response should be monitored by clinical
follow-up, and periodical high-resolution CT should be
considered every 7–10 days during the ﬁrst weeks of
therapy in adults (AIII).
 PCR should not be used for routine diagnosis or treatment
monitoring of IA in SOT recipients (DIII).
 The detection of mould nucleic acid by PCR in BAL or
sputum of a transplant patient should be considered,
particularly in lung/heart transplant patients due to the
subsequent risk of invasive infection (BII). In any case, these
procedures should be considered experimental, and the
results need to be validated.
 The detection of b-D-glucan in serum may be helpful in the
diagnosis of IFD (other than cryptococcosis and mucormy-
cosis), together with the clinical-radiological criteria and
the immunosuppressive-host criteria, although false-positive
results have been reported (B-II). The detection of
cryptococcal antigen in serum or CSF and the detection
of positive blood cultures, skin cultures (in the case of
compatible lesions) and urine cultures are the main
diagnostic techniques for patients with suspected crypto-
coccosis (AII).
 If cranial fungal infection is suspected, CT (BII) or MRI (AII) is
recommended.
 MRI is more sensitive than CT for detecting cryptococcomas
[70] (A-II).
 For sinonasal fungal infection, CT and MRI is recommended
(AIII).
 For skin and soft tissue fungal infections, MRI is the
recommended imaging technique (AIII).
 Ultrasound (BIII), CT or MRI (AII) are the recommended
techniques for fungal abscesses in the liver, kidney or spleen.
 CT is more sensitive than ultrasound for detecting liver
microabscesses (BIII).
Prevention
Correct identiﬁcation of patients at increased risk of fungal
infection is key to IFD prevention. The selection of universal
prophylaxis vs. targeted prophylaxis is based on the type of
transplant. Choice of prophylaxis must bear in mind the
effectiveness, safety, side-effects and drug interactions of the
antifungal agent selected.
Due to the lack of clinical trials and to the epidemiological
differences in IFD in different transplant programmes, there
are no deﬁnitive recommendations for the prevention of IFD
in SOT. The reduction in the incidence of IFD needs to be
analysed together with other measures that may be more
important than the use of prophylaxis with antifungals, such as
optimization of surgical procedures, the proper handling of
immunosuppression and environmental control of certain
ﬁlamentous fungi [72]. Invasive candidiasis is the most frequent
infection in SOT, but invasive aspergillosis carries a higher
morbidity and mortality and, given that they share risk factors,
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prevention strategies for these entities must be combined in
certain transplant populations.
It is generally accepted that universal prophylaxis should not
be routinely used for Candida spp. infection in renal, heart and
lung transplantation. Nevertheless, its use with ﬂuconazole is a
common practice in recipients undergoing intestinal (small
bowel) or pancreas transplantation, given the prominence of
perioperative Candida spp. in this type of transplant [73]. The
duration of prophylaxis depends on the persistence of risk
factors, but is recommended for at least 1 or 2 weeks in
pancreas transplant recipients and for at least 4 weeks in
intestinal transplant recipients (see Table 3 for details) [74].
There is a group of high-risk pancreas or intestinal transplant
patients who also need antifungal prophylaxis for invasive
aspergillosis when the attending centre has an incidence of IA of
>5%/year in transplant patients. These are patients who suffer
from acute rejection and poor initial allograft function, who
require haemodialysis or new laparotomy after transplantation,
or who present bacterial or CMV co-infection, anastomotic
problems or over-immunosuppression [75] (Table 3). Patients
who cannot receive ﬂuconazole due to gastrointestinal intoler-
ance or drug interactions may also beneﬁt from a broad-spec-
trum non-azole antifungal prophylaxis (Table 3).
In the liver transplantation setting there is a high-risk category
of recipients who share risk factors for invasive candidiasis and
aspergillosis. In the absence of antifungal prophylaxis, IFD occurs
in 36% of this population [76]. The risk factors are summarized
in Table 2. These high-risk liver transplant recipients should
receive antifungal prevention active against Candida spp. and
Aspergillus spp. [74,77] (Table 3). The duration of prophylaxis is
not clearly determined, but treatment for 3 or 4 weeks or until
resolution of risk factors seems appropriate [78]. The drug of
choice remains controversial. Amphotericin-B lipid formula-
tions have been used in at least six studies, showing a signiﬁcant
reduction of IFD; however, the number of patients enrolled was
too low to conﬁrm a reduction in mortality [76,79–83]. As renal
failure is one of the main risk factors for IFD, the nephrotoxicity
associated with the treatment of lipid formulations of ampho-
tericin B represents a limitation for its use. Echinocandins are
not nephrotoxic, are unlikely to be hepatotoxic, and have
few drug–drug interactions with immunosuppressive agents.
In addition, promising results have recently been published
using echinocandins in preventive studies focusing on high--
risk liver transplant recipients [84–86]. A prospective,
multicentre, non-comparative study with caspofungin showed
an effectiveness of 88.7% in the ITT analysis, although the
hepatotoxicity that appeared in some patients could limit its
use [85].
In an international clinical trial, more than 345 liver
transplant patients at high risk of IFD were randomized to
micafungin or the centre-speciﬁc standard of care (ﬂuconazole,
liposomal-AmB or caspofungin). Micafungin was found to be
non-inferior to the standard of care in preventing IFD in
high-risk liver transplant patients and showed similar safety
outcomes. At the end of prophylaxis, clinical success rates
were 98.6% for micafungin and 99.3% for the centre-speciﬁc
standard of care in the per protocol set, and were conﬁrmed
in the full analysis set (96.5% vs. 93.6%) [87,88].
Although some transplant groups perform universal pro-
phylaxis with ﬂuconazole in the liver transplant population,
there are several doubts about this strategy. In the absence of
risk factors, the frequency of IFD is <4% [86,89,90]. Universal
antifungal prophylaxis for liver transplant recipients has been
associated with increased hepatotoxicity and interactions with
immunosuppressive drugs. Additionally, the appearance of
non-albicans Candida spp. and increasing rates of resistance
have limited the use of ﬂuconazole [91,92].
In heart transplant recipients Aspergillus spp. cause the most
infections, which occur earlier than Candida spp. infections.
Given the absence of clinical trials, there is no clear agreement
among the various groups for recommending antifungal
prophylaxis in these patients; most of them choose to apply
the prevention only to patients at high risk of IFD. One Spanish
study conﬁrmed that the frequency of IA was independently
associated with the need for reoperation, CMV disease,
haemodialysis requirement and the presence of another clinical
case of IA during the previous 2 months at the same centre;
the use of itraconazole was a protective factor [16]. There-
fore, it seems sensible to use antifungal prophylaxis for heart
transplant patients with acute rejection, haemodialysis,
re-exploration after transplantation, CMV disease or excessive
Aspergillus spp. in the air of the centre [16] (Table 3).
Universal prophylaxis against Aspergillus is generally accepted
in lung transplant recipients, although the strategies used vary
widely from centre to centre [93]. The efﬁcacy and advantages of
using nebulized lipid formulations of amphotericin B as antifungal
prophylaxis in lung transplant recipients have been demon-
strated; however, the duration is not well established [15,94–
97]. Moreover, it has recently been shown that amphotericin B
does not cause changes in the lipid content of pulmonary
surfactant, thus adding a safety beneﬁt [98]. The duration is
usually limited to the ﬁrst 3–6 months after transplantation, but
some groups recommend continuation, especially if risk factors
persist [94,99]. The implementation of this prophylaxis protocol
has been associated with an incidence of IA of 4.8% [99].
The main advantages of nebulized prophylaxis are: lack of
drug–drug interactions due to the absence of systemic admin-
istration, the cost-effectiveness relationship and the ability to
achieve high levels of lung antifungal concentrations without
systemic side-effects [100]. One disadvantage is local irritation
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with secondary effects such as cough or bronchospasm. These
effects occur in fewer than 10% of patients, and the use of
salbutamol or halving the drug concentration can improve the
symptoms. Other disadvantages are the need for the patient or
family members to know how to administer them and the need
for appropriate equipment. The possibility of irregular distribu-
tion of the drug in the lung is another potential limitation [101].
Alternatively, antifungal prophylaxis can be performed with
azoles such as itraconazole or voriconazole. Husain et al. [102]
studied the effectiveness and safety of voriconazole as
universal prophylaxis in lung transplant patients; the overall
incidence of IA was 1.5% in the universal prophylaxis group
receiving voriconazole, compared with 23.5% in the targeted
prophylaxis group [102]. However, an increase in liver
enzymes was observed in 37–60% of patients receiving
voriconazole and 14% had to discontinue the drug due to
adverse effects [102]. Other studies have conﬁrmed this
associated hepatotoxicity [103,104]. What is more, skin
cancer has been reported in lung recipients with the prolonged
use of voriconazole [105–107], and also in patients experi-
encing chronic phototoxicity [108].
There is no agreement about the prevention strategy for
late IA (>90 days post-transplant). This is a signiﬁcant problem,
because half of the IA cases at some centres occur late. In
general, patients with high risk of late IA are those with
chronic rejection, allograft dysfunction due to HCV (liver
transplant), haemodialysis and over-immunosuppression and
transplant-related neoplasms. In these situations, prophylaxis
should be considered [9,74].
As voriconazole cannot be given to children below 2 years
old, liposomal amphotericin B is the preferred mould-active
preventive antifungal agent in this age. Among echinocandins,
caspofungin and micafungin are authorized for administration
to children <2 years of age, whereas anidulafungin is currently
under study for patients <18 years. In general, there are no
randomized or large cohort studies in paediatric SOT recip-
ients; therefore, the therapeutic recommendations for these
patients are largely based on efﬁcacy studies in adults
combined with safety studies in children.
Recommendations for the prevention of IFD in SOT
The recommendations for the prevention of IFD are described
in Table 3.
Treatment
Invasive candidiasis
There are no randomized or cohort studies of the treatment
of invasive candidiasis in SOT recipients; therefore, the
therapeutic recommendations for these patients are based
on different randomized studies of heterogeneous patient
groups, which include a low proportion of SOT patients [109].
For this reason, most recommendations are evidence level III.
The usual treatment for Candida infections in transplant
recipients is no different from that administered to non-neu-
tropenic patients, although some aspects related to drug-drug
interactions and potential toxicities associated with the use of
the azoles should be considered [78,110].
Administration of certain antifungals is limited in solid organ
recipients. Amphotericin B deoxycholate should not be used in
SOT due to its nephrotoxicity, especially in patients receiving
calcineurin inhibitors. All the azoles interact with these inhib-
itors because their metabolism depends on cytochrome P450;
therefore, it is very important to determine plasma levels of both
azoles and immunosuppressive agents. Echinocandins (caspo-
fungin, anidulafungin and micafungin) have shown high success
rates for the treatment of invasive candidiasis [111]; they
generally have fewer side-effects, less nephrotoxicity and fewer
drug–drug interactions in SOT recipients than the other
antifungals mentioned. Additionally, they are active against
Candida strains that are resistant to azoles.
The usefulness of echinocandins for treating C. parapsilosis is
controversial because minimal inhibitory concentrations are
higher than those of other Candida species [112]. Some studies
have observed similar outcomes when comparing different
echinocandins vs. amphotericin B or ﬂuconazole [111,113,114].
However, if the catheter cannot be removed, a lipid formulation
of amphotericin B or an echinocandin should be used [112,115].
The ﬁrst measure to be adopted, whenever possible, is the
removal of central venous catheters. This measure has been
associated with lower mortality in neonates and non-neu-
tropenic patients [116]. Appropriate ophthalmological exam-
ination is also recommended in patients with candidaemia.
In non-neutropenic transplant recipients who have not
recently received azoles and do not present moder-
ate-to-severe infection or signiﬁcant liver damage, several
guidelines recommend the use of ﬂuconazole for invasive
candidiasis (12 mg/kg ﬁrst dose, followed by 6 mg/kg/day)
[110]. In children <12 years, the dose of ﬂuconazole is 12 mg/
kg/day (possibly with a loading dose of 25 mg/kg). However,
we prefer the use of echicocandins [75]. It should be noted
that even when the patient has no signs of clinical severity,
most cases of invasive candidiasis occur in the immediate
post-transplant period, mostly in the intensive care unit.
Moreover, SOT patients sometimes suffer from renal failure or
require haemodialysis. In this situation, the dosage of immu-
nosuppressants is itself complicated. Treatment with azoles,
particularly at these high doses, entails toxicity problems and
drug–drug interactions with immunosuppressants and their
ª2014 The Authors
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levels must be measured. It is also important to assess
voriconazole levels in the case of neurological manifestations
and posaconazole levels in the case of diarrhoea or mucositis,
which will signiﬁcantly reduce absorption.
Transplant recipients are frequently affected by candiduria,
especially kidney and pancreas recipients. Treatment of
asymptomatic candiduria is generally discouraged unless the
patient is undergoing a urological procedure. In symptomatic
patients, urinary catheters should be withdrawn or replaced
and candiduria should be treated for 7–14 days [110]. The
treatment of signiﬁcant candiduria due to a ﬂuconazole-resis-
tant species is difﬁcult, as neither echinocandins nor lipid
formulations of amphotericin B achieve satisfactory levels in
the urinary tract.
Recommendations for the treatment of invasive candidiasis in SOT
[78,112].
 Candidaemia:
○ In non-neutropenic transplant recipients, initial treatment
with echinocandins is strongly recommended (AIII).
Alternatively, liposomal amphotericin B can be used
despite the risk of nephrotoxicity, especially in kidney
transplant recipients (AIII). Fluconazole would be mar-
ginally recommended (CIII). Similar recommendations can
be given for children with SOT.
○ Neutropenia is uncommon in SOT; however, if candi-
daemia occurs in this context initial treatment with
echinocandins or liposomal amphotericin B as fungicidal
agents is mandatory (AIII).
○ Once the Candida spp. is isolated, it is important to
perform an antifungal susceptibility test. If C. parapsilopsis
is isolated, ﬂuconazole (BIII) or liposomal amphotericin
B (AIII) could be used as an alternative.
○ All central venous catheters must be removed (though
not over a guidewire) (AII). When catheter removal is
not possible, and if the patient is in an unstable
condition, antifungal-lock therapy with a lipid-based
amphotericin B formulation or echinocandin could be
considered (CIII). Azoles or amphotericin B deoxycho-
late should be avoided (DIII).
○ To specify the duration of treatment a fundoscopic
examination is mandatory. Resolution of candidaemia
should be established by performing at least one blood
culture per day until culture results are negative (AIII).
○ In patients with a central venous catheter, the possibility
of a thrombus has to be ruled out (AIII).
○ For uncomplicated candidaemia, treatment for 14 days
after resolution is recommended (AIII). Patients with
metastatic complications require longer therapy (AIII).
○ To simplify treatment, switching to oral ﬂuconazole
could be considered after 10 days of IV therapy when
Candida spp. are susceptible, the patient is stable,
tolerates oral administration and the drug–drug inter-
actions on CYP3A4 metabolism can be managed (BIII).
○ If C. glabrata or C. krusei is isolated the use of echino-
candin (BIII) or liposomal amphotericin B as an alterna-
tive should be considered (BIII).
 Urinary Tract Infections (UTIs):
○ Asymptomatic candiduria should not be treated, unless
the patient is undergoing a urological procedure or is
neutropenic (AIII). Treatment of symptomatic patients
with candiduria (cystitis) or pyelonephritis is required
(AIII). In symptomatic UTI SOT recipients with candi-
daemia the candidaemia recommendations described in
the section above should be followed.
○ Removal of the urinary catheter is advisable (AIII).
○ An imaging technique should be considered to rule out
abscess, fungus ball or urological abnormality (AIII).
○ When a urinary fungus ball is diagnosed, surgical removal
is strongly recommended (AIII).
○ For patients with UTI due to a ﬂuconazole-susceptible
Candida spp. treatment with ﬂuconazole is strongly
recommended (AIII). For recipients with ﬂuconaz-
ole-resistant organisms, lipid formulations of amphoter-
icin B  oral ﬂucytosine are the treatment of choice
(AIII).
○ Echinocandins achieve poor urinary levels; therefore,
these antifungals are precluded for the treatment of UTI
(DIII).
○ Amphotericin B deoxycholate bladder irrigation (50 mg
amphotericin B per litre of sterile water) continuously
for 5–7 days may be an efﬁcacious treatment. Liposomal
amphotericin B may be effective as adjunctive therapy
for a urinary fungus ball (BIII).
 In lung transplant recipients with anastomotic tracheobron-
chitis due to Candida spp. the recommended treatment is
nebulized liposomal amphotericin B 25 mg three times a
week, or nebulized amphotericin B lipid complex every
other day plus removal of the debris by repeated bron-
choscopies (AIII). Echinocandins may be more effective than
azoles for Candida spp. growing in the bioﬁlms of the
anastomoses (BIII).
 In Candida endocarditis, either native or prosthetic, surgery
within a week or even earlier is recommended (AII). The
treatment of choice is liposomal amphotericin B (5 mg/kg/
24 h)  ﬂucytosine 25 mg/kg/6 h for 6–8 weeks (BII), fol-
lowed by ﬂuconazole (BII) for sequential treatment in stable
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patients [78,111]. Patients who are inoperable need sup-
pression of the infection with combined ﬂuconazole 400–
800 mg [117] (CII). In view of reports of the efﬁciency of
caspofugin  ﬂucytosine, this regimen can be recommended
as initial treatment (BII) [118].
 In ocular candidiasis, echinocandins diffuse poorly to the
retina; therefore, liposomal amphotericin B either alone or
combined with ﬂucytosine is recommended when the
susceptibility of the isolate is unknown (AII). In susceptible
isolates ﬂuconazole or voriconazole are the drugs of choice
(AII). In the case of vitreal involvement, vitrectomy and
intravitreal injection of amphotericin B are recommended in
addition to systemic therapy (AII).
 For detailed recommendations for treatment of Candida
diseases, readers should refer to Cornely et al. [112],
ESCMID guideline for the diagnosis and management of
Candida diseases 2012: non-neutropenic adult patients.
Invasive Aspergillosis
The emergence of lipid amphotericin B formulations in the
1990s improved the prognosis of IA in the SOT population.
However, no new studies with these drugs have been published
since then and it is difﬁcult to assess the therapeutic response.
The CLEAR (Collaborative Exchange of Antifungal
Research) study analysed 721 immunosuppressed patients
with IFD treated with amphotericin B lipid complex. The study
included 109 solid organ recipients with IA, of whom 54% had
a favourable response [119].
Voriconazole is authorized for the treatment of IA in solid
organ recipients based on the results of a small-scale, non-com-
parative, open-label European trial [120] and on a trial that
compared voriconazole and amphotericin B deoxycholate as
initial treatment in patients with haematological malignancy
[121]; however, the latter study included only 11 solid organ
recipients. Although the experience of SOT groups with
voriconazole is considerable, few data have been published to
date [122–124].
Historically, the mortality of IA when the CNS is affected
has been close to 100%. Voriconazole has improved the
prognosis of patients suffering from this disease, due to its
penetration into the CNS. Schwartz et al. [125] conﬁrmed a
partial or complete response in 35% of patients with CNS
involvement in combination with neurosurgical management.
Caspofungin is the only echinocandin approved by the FDA
and EMA for the treatment of refractory IA. In a study of 12
thoracic organ recipients, caspofungin demonstrated an efﬁ-
cacy of 86% [126]. Maertens et al. [127] recently conﬁrmed a
favourable response in six of nine solid organ recipients. In an
observational study of 19 SOT recipients, Winkler et al. [128]
found a favourable response with caspofungin used as ﬁrst-line
treatment in 78% of patients receiving monotherapy and in
70% of those receiving combination therapy.
The role of combination therapy in solid organ recipients with
IA has not been deﬁned. One multicentre study analysed the
outcomes of 40 patients who received voriconazole and
caspofungin as initial treatment for IA [129], and compared this
group with a historic cohort who received a lipid formulation of
amphotericin B. Multivariate analysis revealed that combination
therapy reduced 90-day mortality in the subgroup of patients
with renal insufﬁciency and IA caused by A. fumigatus [129].
To date, the published experience with posaconazole or
micafungin for treating SOT recipients with IA is limited, but
the few outcomes described are satisfactory [130–132]. Few
data are available for anidulafungin [84].
Recommendations for the treatment of invasive aspergillosis in SOT
[75,133].
 General principles:
○ Antifungal therapy should be initiated early in SOT
patients with high suspicion of IA (AIII).
○ Treatment should be individualized according to type of
transplant, SOT recipient, type of IA and immunosup-
pression used (AIII).
○ Diagnostic evaluation is mandatory in order to conﬁrm
the IA (AIII)
○ It is important to reduce immunosuppression as an
adjunct to antifungal treatment, but without jeopardizing
graft viability. Probably the most important strategy is
the reduction of the corticosteroid dose (BIII). There is
an added risk of steroid myopathy with combination
treatment of voriconazole and methylprednisolone at
doses above 20 mg/day (BIII).
 The preferred treatment for IA as a primary approach is
voriconazole (4 mg/kg/12 h with a loading dose of 6 mg/kg
or 200 mg/12 h PO with a loading dose of 400 mg/12 h PO)
(AIII) or liposomal amphotericin B (3 mg/kg/day) (AIII). In
children, the dose of voriconazole is 8 mg/kg/12 h IV with a
loading dose of 9 mg/kg.
 If voriconazole is used in severely ill patients, a parenteral
formulation is recommended in order to ensure bioavail-
ability. If renal impairment is present or if the patient is
clinically stable, the drug can be administered orally.
Monitoring plasma levels is recommended in order to
maintain the range between 2 and 4 mg/L (AII). The
potential hepatotoxicity should be considered, especially in
liver transplantation, and drug–drug interactions with im-
munosuppressants (AIII).
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 In patients for whom administration of voriconazole is
problematic (due to risk of liver toxicity, severe drug–drug
interaction, intolerance or allergy to azoles), liposomal
amphotericin B is recommended (AIII). Physicians should be
aware of the increased risk of nephrotoxicity (AIII).
 If the patient has severe disease (pneumonia or disseminated
disease), initial treatment with a combination of antifungals
should be considered, at least to ensure therapeutic
concentrations of voriconazole (AIII). Elective treatment
with voriconazole plus caspofungin is a possibility [129]
(loading dose 70 mg/24 h followed by 50 mg/24 h) or
voriconazole plus anidulafungin (loading dose 200 mg/24 h,
then 100 mg/24 h) (A-III). In children, caspofungin is given
with a dose of 50 mg/m2 with a loading dose of 70 mg/m2. In
patients for whom administration of voriconazole is prob-
lematic (see above), liposomal amphotericin B plus caspo-
fungin may be an alternative (BIII).
 The therapeutic response should be monitored periodically
by a clinical follow-up and a high-resolution CT scan.
Performance of a CT scan every 7–10 days during the ﬁrst
weeks should be considered (AIII). It should be noted that
neither a cavitation of lesions indicating necrosis nor a slight
increase in lesion volume (especially in the context of
recovery after absolute neutropenia) indicates adverse
outcome (AIII).
 Rescue treatment is the treatment of infected patients who
are refractory or intolerant to initial therapy. The point in
time when treatment is considered a failure is not well
deﬁned. The following results are associated with poor
outcome and may be considered as therapeutic failures in
the absence of clinical improvement: (i) dissemination of the
clinical symptoms during treatment, (ii) new or increased
lesions in the CT scan performed 7–10 days after treatment
onset (in the absence of recovery from absolute neutrope-
nia), (iii) no decrease in lesion size in the CT scan performed
at 15–21 days, or (iv) intolerance to elective therapy. In the
presence of these ﬁndings, a switch to a different kind of
antifungal to the one used for the initial treatment is
recommended (AIII).
 In the case of rescue treatment due to failure of the
treatment of choice, a combination of antifungals is strongly
recommended (AIII). The recommendations are the same as
those discussed above in the severe IA section (pneumonia
or disseminated disease).
 In the case of rescue therapy due to intolerance of the
treatment of choice, a change to voriconazole or liposomal
amphotericin B should be considered if it is not contrain-
dicated (AIII). Other antifungal agents with conﬁrmed
effective use as rescue therapy include: amphotericin B lipid
complex 5 mg/kg/day (BII), posaconazole 400 mg/12 h (BIII),
caspofungin loading dose 70 mg/24 h followed by 50 mg/
24 h (BIII) and micafungin 150–200 mg/24 h (BIII).
 Surgery is recommended in patients with massive haemopt-
ysis, endocarditis, sinus disease or infection of the pericar-
dium and large vessels. The beneﬁt of surgery is doubtful
when there is bone involvement [134].
 In endocarditis, given the poor prognosis of medical
treatment alone, surgery is recommended as well as
replacement of valves or affected tissues (BIII) [135]
(Table 4).
 Although the duration of treatment has not been estab-
lished, it should be maintained until radiological signs
disappear, which is usually a minimum of 6–12 weeks.
Treatment with oral voriconazole could be extended for a
few weeks in order to treat possible residual microfoci of
aspergillosis.
 Special considerations for lung transplantation:
 Colonization must be treated to prevent invasive disease
(AIII). The recommended treatment is nebulized liposomal
amphotericin B 25 mg/24 h for 7 days, then 25 mg/72 h, or
nebulized amphotericin B lipid complex 50 mg/24 h once
every 2 days plus removal of the debris by repeated
bronchoscopies In the case of intolerance or difﬁculties
inhaling lipid formulations of amphotericin B, voriconazole
TABLE 4. Surgery criteria for invasive Aspergillosis in SOT
Organ involvement Recommendation
Injuries close to large vessels and/or pericardium Resection of the lesion
Pericardium involvement Pericardiectomy
Chest wall invasion by lung injury Chest injury and chest wall resection is needed (possible later reconstruction)
Empyema Chest tube drainage is required or even surgical drainage and thoracotomy (whether organized or inﬁltrative)
Haemoptysis secondary to a pulmonary lesion Cavity resection vs. embolization
Skin and soft tissue involvement Debridement and resection with wide margins
Endocarditis Remove all devices
Vegetation and infected valve resection is required
Osteomyelitis Debridement and cleaning of the affected tissue, with subsequent possibility of reconstruction is required
(musculoskeletal grafts or bone grafts)
Sinusitis Cleaning, curettage and resection of affected tissue is needed
Central nervous system involvement Resection and withdrawal of affected tissue and space-occupying lesions is required
Endophthalmitis/panophthalmitis Vitrectomy, evisceration or enucleation, as required
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should be considered (loading dose 400 mg/12 h PO, then
200 mg/12 h PO) (BIII).
 In the case of nodular or ulcerative tracheobronchitis,
voriconazole plus nebulized lipid formulations at the same
doses as those used for colonization episodes are recom-
mended (AIII). Bronchoscopy is also recommended to
evaluate the extension of disease and to clear necrotic
debris and fungus balls (this should be repeated every week
or every 2 weeks). A high-resolution CT scan should also be
performed to rule out parenchymal extension (AIII).
 Long-term treatment with voriconazole may induce liver
toxicity and may be associated with development of cutane-
ous squamous cell carcinoma with high clinical aggressiveness
[105,106,136] (BIII).
Cryptococcosis
The treatment of cryptococcal infection varies according to
the localization of the disease. For cryptococcal meningitis, the
essential drug is amphotericin B. Several studies have shown
better results using high doses of amphotericin B in this
situation [137,138]. The use of lipid formulations has been
associated with lower rates of mortality [139,140]. Several
studies have shown that the combination of ﬂucytosine with
amphotericin B for induction treatment is associated with
better response rates than amphotericin B alone, a greater
speed in the sterilization of cultures and a better clinical
outcome [141–143]. Although it is not clear that this beneﬁcial
effect also occurs with the combination of lipid amphotericin B
[144], this combination therapy is recommended in SOT
patients whenever possible [23] in order to avoid nephrotox-
icity. Nevertheless, a recent multinational study of 83 trans-
plant recipients and the review of 168 cases published in the
literature conﬁrmed that only one-third of patients received
concomitant 5-ﬂucytosine, and it was not associated with
poorer sterilization of CSF cultures at 2 weeks. In this study,
induction treatment was based on a lipid formulation of
amphotericin B in 50% of the patients, and induction with
ﬂuconazole was reserved for the mildest and extrameningeal
forms [145].
The combination of ﬂucytosine with ﬂuconazole has also
produced favourable results, but not as good as the combi-
nation with amphotericin B in some studies [146,147]. The
consolidation treatment is usually performed with ﬂuconazole
(200–400 mg/day) [148]. Other azoles such as voriconazole or
posaconazole have been used in refractory cases with good
response, but there are no studies that demonstrate superi-
ority over ﬂuconazole [149,150]. Some authors recommend
lifelong treatment. Singh et al. [145] conﬁrmed that the median
maintenance treatment was 6 months (55% of patients);
however, in 25% of patients it was maintained for up to
1 year. In comparison to C. neoformans, infection by C. gatii is
associated with more neurological sequelae, a greater need for
surgery and a poorer response; this is probably because of the
reduced activity of ﬂuconazole, the greater frequency of
cryptococcoma and the use of corticosteroids in the presence
of marked perilesional oedema. Extended spectrum azoles may
be an alternative for the maintenance phase. Cryptococcoma
must be removed by surgical resection if they are easily
located. In patients with cryptococcosis, intracranial hyper-
tension must be managed appropriately with repeated lumbar
punctures or placement of a CSF shunt when necessary [151–
153].
An estimated 5–11% of SOT recipients with cryptococcal
disease may develop immune reconstitution inﬂammatory
syndrome (IRIS) due to rapid reduction of immunosuppressive
therapy, typically between 4 and 6 weeks after initiation of
antifungal therapy [145]. The development of IRIS in kidney
transplant patients seems to favour the emergence of chronic
graft dysfunction [154].
There are no speciﬁc recommendations for the treatment
of pulmonary cryptococcosis in SOT recipients, which is
similar to the case of HIV patients [155]. Lower mortality
has been observed when using lipid formulations of ampho-
tericin B rather than conventional amphotericin B in severe
cases [18].
For disseminated infection, the recommendations are the
same as for the treatment of CNS infection. If ﬂucytosine is not
added during the induction phase, the recommendation is to
extend induction treatment for 4–6 weeks. The use of
conventional amphotericin B is discouraged, because there is
a high risk of nephrotoxicity in these patients.
In children cryptococcosis is rare, and there are no speciﬁc
recommendations in this population.
Recommendations for the treatment of cryptococcosis in SOT.
 For meningoencephalitis, disseminated disease or diffused
pulmonary inﬁltrates and acute respiratory failure, the
recommended therapy is as follows [23,156]:
○ Liposomal amphotericin B 3–4 mg/kg/day or amphoter-
icin B lipid complex 5 mg/kg/day (AII) plus ﬂucytosine
25 mg/kg/6 h (BII); (monitoring to maintain levels of 30–
80 mg/L 2 h post-dose) for 2 weeks as induction
therapy.
○ Fluconazole 400–800 mg/day for 8 weeks as consolida-
tion (AII).
○ Fluconazole 200 mg/day for 6–12 months as mainte-
nance (AII).
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 For management of increased intracranial pressure [23]:
○ Initial opening pressure must be recorded and if
>25 mmHg a large volume tap should be performed to
reduce the intracranial pressure to <20 mmHg (AII).
○ Lumbar pressure should be performed daily until
opening pressure is <25 mmHg (AIII).
 For focal pulmonary and incidentally detected pulmonary
disease in otherwise asymptomatic patients, the recom-
mended treatment is ﬂuconazole 400 mg/24 h (6 mg/Kg/
24 h) for 6–12 months (AII).
 Whenever possible, a gradual reduction in the net state of
immunosuppression should be performed during therapy
(AIII).
 There is no proven therapy for IRIS. Corticosteroids in
doses equivalent to 0.5–1 mg/kg of prednisone may be
considered for major complications related to inﬂammation
in the CNS and severe manifestations in pulmonary or other
sites [157] (BII).
Other ﬁlamentous fungi
There are no speciﬁc recommendations for the management
of these infections in SOT, and the same applies to other
immunocompromised patients. Diagnosis and treatment
guidelines for the rarer IFD (mucormycosis, fusariosis,
scedosporiosis and others) are being prepared by ESCMID.
As with other immunosuppressed patients, management of
mucormycosis in SOT recipients is based on three approaches:
(i) antifungal treatment with high-dose liposomal amphotericin
B; (ii) surgical resection, if possible; and (iii) reduced immu-
nosuppression. As ﬁrst-line therapy in both adults and children
with mucormycosis, liposomal amphotericin B at doses of
5 mg/kg/day or more is administered. Posaconazole is a
second-line treatment if amphotericin B is contraindicated
[130,158]. For CNS mucormycosis, liposomal amphotericin B
is preferred. As adjunctive therapy, recombinant cytokines
such as granulocyte colony-stimulating factor and granulocyte
macrophage-colony stimulating factor can be given to restore
immunosuppression. Iron chelators such as deferasirox [159]
have not been shown to assist clinically. Echinocandins can be
used in combination with amphotericin B [160]. High doses of
lipid amphotericin B (10–15 mg/kg/day) have been used in
refractory forms and/or in cases of CNS involvement, although
their efﬁcacy has not been compared in humans at doses of
5 mg/kg/day and they are more toxic. Promising results have
nevertheless been obtained with 10 mg/kg/day in a pilot
multicentre study [161].
Good results have been reported with posaconazole in
patients who have previously received amphotericin B
[130,158]; however, the combination of posaconazole and
amphotericin B has not proven beneﬁcial in the prevention of
murine experimental mucormycosis [162]. Reed et al. [160]
TABLE 5. Emerging fungal infections in SOT
Microorganism Treatment Comments
Zygomycetes Lip-AB high dose (up to 15 mg/kg q24 h if tolerated);
most data document maximum beneﬁt achieved at 7.5 mg/kg q24 h
Lip-AB 5 mg/kg q24 h + caspofungin
Posaconazole as alternative
Surgical resection if amenable
Reduction of immunosuppression
Control of predisposing metabolic conditions
Correction of neutropenia
Fusarium F. solani and F. verticillioides Lip-AB 5–15 mg/kg q24 h
F. oxysporon more susceptible to extended-spectrum triazoles
Surgical resection of localized skin disease
Removal of infected foreign bodies such as intravascular catheters
Correction of neutropenia
Scedosporium S. apiospermum: voriconazole
S. proliﬁcans:
Resistant to all antifungal agents. Surgical debridement is mandatory.
Combination antifungal options:
Echinocandin + AmB or voriconazole Voriconazole + terbinaﬁne
Surgical resection or debridement is highly recommended
Drainage of abscesses and resection of any infected foreign body
Correction of neutropenia when present
Paecilomyces Voriconazole
Posaconazole
Surgical excision or debridement is recommended
Penicillium Lip-AB 2 mg/Kg q24 h followed by maintenance with
itraconazole 400 mg q24 h
Scopulariopsis Posaconazole or voriconazole + terbinaﬁne
Posaconazole or voriconazole + caspofungin
Debridement of infected tissue
Removal of involved foreign bodies
Trichoderma Lipid AmB + voriconazole or posaconazole until
susceptibility data are available
Removal of infected peritoneal dialysis catheters
Surgical drainage/removal of localized lesions such as pulmonary mycetomas,
sinus collections, abdominal and brain abscesses
Phaeohyphomycosis Voriconazole
Posaconazole
Itraconazole
Surgical debridement is recommended
In vitro synergy:
Lipid AmB + ﬂucytosine
Itraconazole + ﬂucytosine
Fluconazole 800 mg q24 h
Extended-spectrum triazoles
Identiﬁcation in urine in kidney transplant recipients generally does not
require treatment
Sporothrix AmB until response, followed by itraconazole (total of 12 months) Itraconazole may be considered for cutaneous disease
Malassezia Fluconazole 400–800 mg q24 h
Lip-AB B 3–5 mg/kg q24 h
Removal of intravenous catheters
Lip-AB, lipid amphotericin B; Lipid AmB, lipid formulations amphotericin B.
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TABLE 6. Drug Interactions of Azoles
Azoles Drug A
(FLU, ITRA, VOR, POS)
Drug B Effect Recommendation
Antacid
H2 antagonist
Cimetidine
Famotidine
Ranitidine
↓↓ ITRA conc
Cimetidine POS ↓↓ conc
Avoid/ Use Alternative ITRA
Avoid/ Use Alternative combination Cimetidine /POS
If necessary use Famotidine or Ranitidine
Antacids/ITRA
Aluminum Hydroxide
Calcium Carbonate
Magaldrate
Magnesium Carbonate
Magnesium Hydroxide
Magnesium Trisilicate Sodium Bicarbonate
↓ absorption of A
↓ A conc
Consider therapy modiﬁcation
Apply primarily to itraconazole capsules
Oral suspension may be less sensitive to the effects
of gastric acidity
Administer itraconazole at least 1 h after and 2 h before
administration of any antacids
Antiepileptic drugs
Carbamazepine
Fosphenytoin
Oxcarbazepine
Phenytoin
↓↓ A conc
↑↑ B conc
A, B; increase ++ metabolism CYP3A4
A, B ↓↓ CNI, mTOR inhibitors conc a
Avoid/ Use Alternative
Consider use other non-azole antifungal drug
Partial Seizures: Consider Valproic acid, Gabapentin, Pregabalin,
Lacosamide
Acute repetitive seizures or status epilepticus: Consider IV
Lorazepam
Barbiturates
Secobarbital
Pentobarbital
Phenobarbital
↓↓ A conc
B increase ++ metabolism CYP3A4
B ↓↓ CNI, mTOR inhibitors conc a
Avoid/ Use Alternative
Benzodiazepines
Alprazolam
Bromazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Diazepam
Estazolam
Flurazepam
Midazolam
Nitrazepam
Triazolam
Zolpidem
↑ B conc Avoid/Use Alternative or
Consider therapy modiﬁcation
Consider Lorazepam, Oxazepam, or Temazepam or
Decrease benzodiazepine dose
Busulfan May ↑ B conc Monitor adverse events
Calcium Channel Blockers (CCB)
Amlodipine
Diltiazem
Felodipine
Isradipine
Nicardipine
Nifedipine
Nisolpidine
Verapamil
↑ conc Verapamil, diltiazem, nicardipine
amlodipine ++
B, A; inhibition metabolism CYP3A4:
↑ CNI, mTOR inhibitors conc b
Nifedipine, isradipine
No effect metabolism CYP3A4
Consider Avoid/ Use Alternative
If clearly indicated:
Consider use other non-azole antifungal drug
CCB dose reduction is needed
Monitor toxic effects CCB
Consider avoid mTOR inhibitors
or
Consider Nifedipine, isradipine
TDM CNI closely
Cilostazol ↑ B conc Reduce Cilostazol doses to 50 mg q12 h
Clopidogrel ↓ B efﬁcacy VOR, FLU Avoid VOR, FLU / Use Alternative
Colchicine ↑↑ B serum conc
CNI ↑ B conc
Reduce colchicine dose
Cyclosporine ↑ B conc Consider therapy modiﬁcation
Reduce B dose mandatory:
FLU: Dose dependent. By 20- 50%;
VORI: by ½;
POS: by ¼.
Monitor TDM Cyclosporine closely
Diclofenac VORI ↑ B conc Consider therapy modiﬁcation
Consider using a lower dose of diclofenac. Max 50 mg q12 h
Digoxin ITRA, POSA ↑ B conc
Tacrolimus ↑ B conc
Monitor for increased serum conc/effects Digoxin
Docetaxel ↑ B conc Use Itraconazole with Caution and if Clearly Indicated
Monitor for toxic and increased effects of Docetaxel
Consider therapy modiﬁcation
Consider use a non azole antifungal
Eletriptan ITRA, VORI, POSA ↑ B conc Avoid combination
Consider sumatriptan
Ergot alkaloids ↑ B conc Avoid ITR, VOR, POS / Use Alternative
Consider use other non-azole antifungal drug
FLU: Decrease doses of Ergot alkaloids.
Monitor for increased toxicity
Fentanyl ↑ B conc
Cyclosporine ↑ B conc
Avoid VOR, POS, ITRA / Use Alternative
Consider therapy modiﬁcation FLU, ITRA,
Decrease dose fentanyl
Monitor adverse events fentanyl
Haloperidol ITRA, VORI, POSA ↑ B conc
B Moderate Risk QTc-Prolonging Agents
Consider Avoid Combination/ Use Alternative
Use only if Clearly Indicated
Highest Risk QTc-
Prolonging Agents /
QTc-Prolonging
Agents
Amiodarone
Artemether
Astemizole
Cisapride
A Enhance the QTc-prolonging effect of B
CNI Enhance the QTc-prolonging effect of B
Consider Avoid Combination/ Use Alternative
Risk of torsades de pointes or potentially life-threatening ventricular
tachyarrhythmias
Consider use other non-azole antifungal drug
Combinations should only be undertaken with caution and should
be avoided when possible
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Table 6 (Continued)
Azoles Drug A
(FLU, ITRA, VOR, POS)
Drug B Effect Recommendation
Citalopram
Disopyramide
Dronedarone
Escitalopram
Flupentixol
Halofantrine
Procainamide
Quinidine
Quinine
Saquinavir
Sotalol
Sparﬂoxacin
Telithromycin
Terfenadine
Isoniazid ↓ ITRA conc
↑ VOR conc
Avoid ITRA or Use only if Clearly Indicated
Risk failure antifungal treatment
Consider therapy modiﬁcation
TDM itraconazole and increase dose
VOR: Risk toxicity TDM VOR
Ibuprofen VOR ↑ B conc by two fold Consider therapy modiﬁcation or other analgesic
Lomitapide ↑ B conc Avoid
Macrolides
Erythromycin
Clarithromycin
Azithromycin
↑ A conc
↑ B conc
A, B Synergism inhibition metabolism CYP3A4:
↑↑ CNI, mTOR conc b
Avoid Erythromycin/Use Alternative
Consider therapy modiﬁcation
Use ONLY if Clearly Indicated
Consider use azithromycin
Consider use other non-azole antifungal
Metoclopramide Metoclopramide ↓ POS conc Consider therapy modiﬁcation
Increase dose POS. TDM
mTOR
Sirolimus
Everolimus
↑ mTOR conc b Avoid Combination VOR, POS/ Use Alternative
Consider therapy modiﬁcation FLU, ITRA
FLU, ITRA: Reduce mTOR dose by ½; TDM closely mTOR
Oral hypoglycemic
Glimepiride
Glipizide
Glyburide
↑ B conc
Increased risk of hypoglycemia
Consider therapy modiﬁcation
Monitor glycaemia closely
Metformin NO interactions with azole antifungals
PDE5 inhibitor
Sildenaﬁl
Tadalaﬁl
Vardenaﬁl
↑ B conc Consider therapy modiﬁcation
Decrease dose PDE5 inhibitor
Monitor patients for effects such as hypotension, headache,
visual changes, and priapism
Proton Pump Inhibitors
Omeprazole
Lansoprazole
Pantoprazole
↓↓ ITRA
↓↓ POS conc by 50%
↑ VOR conc
↑ B conc
B, A; ↑ CNI, mTOR inhibitors conc b
Consider therapy modiﬁcation VOR/POS/ITRA
ITRA Avoid ITRA capsules. Use ITRA Oral solution or ITRA with
an acidic beverage (eg, cola)
POS Increase dose of POS. TDM POS
VOR: Omeprazole ≥40 mg/day or greater: Reduce omeprazole
dose by ½ when initiating VOR. TDM VOR.
Consider use Lansoprazole Pantoprazole (less interaction)
Ranolazine ↑↑ B conc Avoid Combination / Use Alternative
Contraindicated by manufacturer
Red Yeast Rice ↑ B conc Avoid
Conc of Lovastatin and related compounds found in Red
Yeast Rice may be increased.
Rifabutin Rifabutin AUC increased by 80%
↓↓ A conc
B increase ++ metabolism CYP3A4
↓↓↓ CNI, mTOR inhibitorsa
Avoid Combination/ Use Alternative OR
Consider therapy modiﬁcation
Use ONLY if Clearly Indicated
Monitor adverse events of rifabutin
If necessary, doses of rifabutin may be decreased +++
Rifampin ↓↓↓ A conc
↑ B conc
B increase ++ metabolism CYP3A4
↓↓↓ CNI, mTOR inhibitorsa
Avoid Combination/ Use Alternative
If necessary, consider rifabutin
Rituximab ITRA inhibits action of B Avoid or Use only if Clearly Indicated
Statins
Lovastatin
Simvastatin
↑ B conc
CNI ↑ A conc
Avoid Combination/ Use Alternative
Use pravastatin, atorvastatin
Careful monitoring for myopathy
Tacrolimus ↑ Tacrolimus conc b Consider therapy modiﬁcation
Reduce tacrolimus dose mandatory:
FLU: By 40–50%;
VORI, POS: by ⅓
Monitor TDM closely
Theophylline ↑ B conc Consider therapy modiﬁcation
Venlafaxine ↑ B conc Consider therapy modiﬁcation
Vinca Alkaloids
Vinblastine
Vincristine
VOR, POS, ITRA ↑ B conc
Enhanced neurotoxicity
Avoid. Consider therapy modiﬁcation.
Consider use other non-azole antifungal drug
Stop azole 1 day before until 1 day after chemotherapy
If combination: Dose adjustment of vinca alkaloid should be
considered prior to use
Monitor adverse events Vinca Alkaloids
Warfarine INR could increase Monitor INR closely
aRisk Acute Rejection.
bRisk toxicity Calcineurin inhibitor, mTOR.
FLU: Fluconazole. ITRA: Itraconazole. VOR: Voriconazole. POS: Posaconazole. CNI: Calcineurin inhibitors. TDM: Therapeutic Drug Monitoring.
Note: Readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician. The recommendations enclosed in this table should
not be used to replace or overrule a physician’s judgment. Data from: (i). Johns Hopkins ABX Guide. http://www.hopkinsguides.com/hopkins/ub/index/Johns_Hop-
kins_ABX_Guide/All_Topics/A (ii). Sanford Guide Web Edition 2: http://webedition.sanfordguide.com (iii). Lexicomp. Lexi-InteractTM Online. Lexi-InteractTM. http://www.uptodate.
com/crlsql/interact/frameset.jsp.
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recently reported their preliminary experience with
combinations of caspofungin and lipid formulations of
amphotericin B used to treat mucormycosis. A triple therapy
using lipid amphotericin B, micafungin and deferasirox was
effective in a murine model of mucormycosis [163], but not in
patients [164].
Management of infections by Scedosporium spp. is also based
on correction of underlying factors. Surgery can improve
outcome, especially in the treatment of processes such as
sinusitis, keratitis, arthritis, osteomyelitis and brain abscess.
Voriconazole is the treatment of choice, especially in infections
by S. apiospermum [165]. In contrast, S. proliﬁcans is resistant
to most antifungals [166]. A recent multicentre study
conﬁrmed the usefulness of voriconazole in the treatment of
107 patients with severe infections caused by Scedosporium
spp., some of whom were transplant recipients [165]. The
study showed that 57% of patients responded to voriconazole,
and that the response was signiﬁcantly better in infections
caused by S. apiospermum (64%) than in those caused by
S. proliﬁcans (44%). S. proliﬁcans is uniformly resistant to all
common antifungals such as amphotericin B, ﬂucytosine,
ﬂuconazole and itraconazole. In vitro studies revealed a synergy
between terbinaﬁne and several azoles (voriconazole and
itraconazole). There is some clinical experience with these
combinations [167].
Infection by Fusarium spp. is exceptional in solid organ
recipients. It should be treated with high doses of lipid
amphotericin B (mainly in infections by F. solanii and F. verti-
cillioides) or voriconazole, together with withdrawal of infected
catheters and resection of necrotic material [168–170].
TABLE 7. Drug Interactions of Azoles with Antiretroviral and anti-HCV drugs
Azoles Drug A (FLU, ITRA, VOR, POS)
Drug B Effect Recommendation
Protease inhibitors
Atazanavir/Ritonavir
Darunavir/Ritonavir (DRV/r)
Fosamprenavir
Lopinavir/ritonavir
Tipranavir
Telaprevir
Boceprevir
FLU: No interaction except Tipranavir:
↑ conc FLU; Tipranavir: ↑ CNI, mTOR inhibitorsa
ITRA: B ↑ conc ITRA
VOR: B ↑ or ↓ conc VOR
POS: B no ↑ or minimum ↓ conc POS
ITRA, VOR, POS: ↑ B conc
B, A; inhibition metabolism CYP3A4:
↑ CNI, mTOR inhibitorsa
FLU: No dose modiﬁcation. Consider Avoid FLU/ Tipranavir
Consider Avoid Comb VOR, ITRA/Protease inhibitors
If Combination clearly needed:
Consider other antifungal drug class OR
Consider POS (less interactions)
Monitor side effects/toxicity Protease inhibitors
TDM POS (if it possible)
Reduce dose CNI ++ mandatory, TDM closely
Check for individual characteristics
NNRTI
Efavirenz
Etravirine
Nevirapine
Rilpivirine
NNRTI Inducer metabolism CYP3A4
↓ CNI, mTOR inhibitors b
Except Rilpivirine
A inhibition metabolism CYP3A4
↑ CNI, mTOR inhibitorsa
Efavirenz ↓↓ POS, VOR, ITRA conc
↑ B conc
Avoid Combination POS, ITRA - Efavirenz/ Use Alternative
If Combination clearly needed
Consider VOR at 400 mg q12 h and efavirenz at 300 mg daily.
Monitor for increased effects/toxicity of efavirenz
TDM VOR
Increase dose CNI, TDM closely
Etravirine ↑↑ B conc; ↓ ITRA Consider therapy modiﬁcation
No preemptive dose adjustment azoles except ITRA
No preemptive dose adjustment Etravirine
Monitor for increased effects/toxicity of etravirine
Consider Avoid mTOR inhibitors,
Increase dose CNI, TDM closely
Nevirapine FLU, ITRA, VOR ↑↑ B conc Avoid Combination ITRA, - Nevirapine/ Use Alternative
Consider therapy modiﬁcation
Avoid mTOR inhibitors, TDM CNI closely
Rilpivirine VOR, FLU enhance the QTc-prolonging
effect of B
CNI Enhance the QTc-prolonging effect of B
Moderate risk
Close monitoring for evidence of excessive QT prolongation
and/or torsades de pointes
NRTI
Didanosine (ddI)
B may ↓ absorption of A Consider therapy modiﬁcation
Concomitant ddI buffered formulations and azoles at
least 2 h apart
Enteric-coated ddI capsules should not interact
Entry and Integrase Inhibitors
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
Quad 
↑↑ VOR, ↑ ITRA conc
VOR ↑↑, ITRA ↑ Elvitegravir, Cobicistat conc
VOR, ITRA, Elvitegravir, Cobicistat inhibition
metabolism CYP3A4:
↑ CNI conc, mTOR inhibitorsa
Avoid combination VOR, ITRA / Use Alternative
Consider therapy modiﬁcation
If clearly indicated consider POS
Decrease dose CNI, TDM closely
Maraviroc A ↑↑ B conc VOR, POS ++ FLU +
mTOR inhibitors ↑ B conc
Consider therapy modiﬁcation
Doses of Maraviroc should be decreased if you
considered combination
If POS use Consider MVC 150–300 mg twice daily.
Consider avoid mTOR inhibitors
Note: Readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician. The recommendations enclosed in this table should
not be used to replace or overrule a physician’s judgment. (i). University of Liverpool: http://www.hiv-druginteractions.org (ii). Johns Hopkins ABX Guide. http://www.
hopkinsguides.com/hopkins/ub/index/Johns_Hopkins_ABX_Guide/All_Topics/A (iii). Sanford Guide Web Edition 2: http://webedition.sanfordguide.com (iv). Lexicomp. Lexi-
InteractTM Online. Lexi-InteractTM. http://www.uptodate.com/crlsql/interact/frameset.jsp.
FLU: Fluconazole. ITRA: Itraconazole. VOR: Voriconazole. POS: Posaconazole. CNI: Calcineurin inhibitors
aRisk toxicity Calcineurin inhibitor, mTOR.
bRisk Acute Rejection.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 27–48
42 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
For the treatment of other emerging and rare fungal
infections, see Table 5.
Recommendations for the treatment of other ﬁlamentous fungi in
SOT.
 The treatment of mucormycosis is based on three
approaches: prompt diagnosis and initiation of therapy,
correction of predisposing conditions as well as reduction of
immunosuppression, and combined medical-surgical treat-
ment (AII).
 The antifungal treatment of choice is liposomal amphotericin
B at doses of 5 mg/kg/24 h or more (B-II). The alternative
treatment is posaconazole (BIII).
 For the treatment of Fusarium spp. the recommendation is
liposomal amphotericin B (BIII) or voriconazole (BIII), along
with the removal of infected catheters and foreign bodies,
and the resection of necrotic material.
 The management of infections caused by Scedosporium spp. is
based on the correction of risk factors, surgical resection of
necrotic material and the removal of any infected foreign
bodies. The antifungal drug recommended is voriconazole,
especially for infections due to S. apiospermum (BII).
Treatment interactions
Drug–drug interactions should be evaluated very carefully in
solid organ recipients. If voriconazole is administered, the
calcineurin inhibitor dose should be reduced by 50–60% [171].
Co-administration of voriconazole and sirolimus is formally
contraindicated, although some authors have applied this
combination by reducing the dose of sirolimus by 75–90%
[172]. If the patient receives posaconazole, then the dose of
tacrolimus or cyclosporine A should be reduced by 60–75%
and 14–29%, respectively [173]. Few drug–drug interactions
affect the echinocandins: caspofungin presents the highest
rate, and anidulafungin the lowest. Other drugs such as
rifampicin, nevirapine, efavirenz, carbamazepine, dexametha-
sone and phenytoin decrease caspofungin concentrations.
Caspofungin administration reduces the concentration of
tacrolimus by 20% [174]. Micafungin can increase sirolimus
concentrations by 20% [175]. Pharmacokinetic studies of
anidulafungin have shown that there is no need to adjust the
dose when administered with other immunosuppressive drugs
[176] (see Tables 6 and 7).
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